🇺🇸 Pregabalin capsule in United States
25 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 25
Most-reported reactions
- Cellulitis — 3 reports (12%)
- Dyspnoea — 3 reports (12%)
- Headache — 3 reports (12%)
- Nausea — 3 reports (12%)
- Oedema — 3 reports (12%)
- Cough — 2 reports (8%)
- Disease Progression — 2 reports (8%)
- Dizziness — 2 reports (8%)
- Flushing — 2 reports (8%)
- Malaise — 2 reports (8%)
Other Neurology; Pain Management; Psychiatry approved in United States
Frequently asked questions
Is Pregabalin capsule approved in United States?
Pregabalin capsule does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Pregabalin capsule in United States?
Guang'anmen Hospital of China Academy of Chinese Medical Sciences is the originator. The local marketing authorisation holder may differ — check the official source linked above.